IOVANCE BIOTHERAPEUTICS INC (IOVA) Fundamental Analysis & Valuation

NASDAQ:IOVA • US4622601007

4.26 USD
+0.51 (+13.75%)
At close: Mar 4, 2026
4.24 USD
-0.02 (-0.47%)
Pre-Market: 3/5/2026, 7:24:17 AM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This IOVA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

We assign a fundamental rating of 2 out of 10 to IOVA. IOVA was compared to 520 industry peers in the Biotechnology industry. IOVA has a bad profitability rating. Also its financial health evaluation is rather negative. IOVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. IOVA Profitability Analysis

1.1 Basic Checks

  • In the past year IOVA has reported negative net income.
  • IOVA had a negative operating cash flow in the past year.
  • In the past 5 years IOVA always reported negative net income.
  • In the past 5 years IOVA always reported negative operating cash flow.
IOVA Yearly Net Income VS EBIT VS OCF VS FCFIOVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • IOVA's Return On Assets of -42.82% is in line compared to the rest of the industry. IOVA outperforms 56.35% of its industry peers.
  • With a decent Return On Equity value of -55.97%, IOVA is doing good in the industry, outperforming 63.08% of the companies in the same industry.
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROIC N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
IOVA Yearly ROA, ROE, ROICIOVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60

1.3 Margins

  • IOVA has a Gross Margin of 28.66%. This is in the better half of the industry: IOVA outperforms 72.50% of its industry peers.
  • IOVA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 28.66%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IOVA Yearly Profit, Operating, Gross MarginsIOVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -10K -20K -30K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. IOVA Health Analysis

2.1 Basic Checks

  • IOVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • IOVA has more shares outstanding than it did 1 year ago.
  • IOVA has more shares outstanding than it did 5 years ago.
  • IOVA has a better debt/assets ratio than last year.
IOVA Yearly Shares OutstandingIOVA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M
IOVA Yearly Total Debt VS Total AssetsIOVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M

2.2 Solvency

  • IOVA has an Altman-Z score of -0.10. This is a bad value and indicates that IOVA is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -0.10, IOVA is in line with its industry, outperforming 59.04% of the companies in the same industry.
  • A Debt/Equity ratio of 0.00 indicates that IOVA is not too dependend on debt financing.
  • The Debt to Equity ratio of IOVA (0.00) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -0.1
ROIC/WACCN/A
WACC8.7%
IOVA Yearly LT Debt VS Equity VS FCFIOVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 3.20 indicates that IOVA has no problem at all paying its short term obligations.
  • IOVA has a Current ratio of 3.20. This is in the lower half of the industry: IOVA underperforms 61.92% of its industry peers.
  • IOVA has a Quick Ratio of 2.83. This indicates that IOVA is financially healthy and has no problem in meeting its short term obligations.
  • IOVA's Quick ratio of 2.83 is on the low side compared to the rest of the industry. IOVA is outperformed by 63.85% of its industry peers.
Industry RankSector Rank
Current Ratio 3.2
Quick Ratio 2.83
IOVA Yearly Current Assets VS Current LiabilitesIOVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. IOVA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 13.85% over the past year.
  • The Revenue has grown by 60.60% in the past year. This is a very strong growth!
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%

3.2 Future

  • The Earnings Per Share is expected to grow by 20.21% on average over the next years. This is a very strong growth
  • IOVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 27.64% yearly.
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue Next Year49.67%
Revenue Next 2Y50.68%
Revenue Next 3Y45.74%
Revenue Next 5Y27.64%

3.3 Evolution

IOVA Yearly Revenue VS EstimatesIOVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M 800M
IOVA Yearly EPS VS EstimatesIOVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -1 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. IOVA Valuation Analysis

4.1 Price/Earnings Ratio

  • IOVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year IOVA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IOVA Price Earnings VS Forward Price EarningsIOVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IOVA Per share dataIOVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1 1.5

4.3 Compensation for Growth

  • IOVA's earnings are expected to grow with 27.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.08%
EPS Next 3Y27.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. IOVA Dividend Analysis

5.1 Amount

  • No dividends for IOVA!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

IOVA Fundamentals: All Metrics, Ratios and Statistics

IOVANCE BIOTHERAPEUTICS INC

NASDAQ:IOVA (3/4/2026, 8:00:03 PM)

Premarket: 4.24 -0.02 (-0.47%)

4.26

+0.51 (+13.75%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)05-06
Inst Owners54.61%
Inst Owner Change16.53%
Ins Owners0.32%
Ins Owner Change10.1%
Market Cap1.75B
Revenue(TTM)263.50M
Net Income(TTM)-390.98M
Analysts78.82
Price Target9.29 (118.08%)
Short Float %34.58%
Short Ratio9.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)1.11%
Min EPS beat(2)-2.78%
Max EPS beat(2)5%
EPS beat(4)1
Avg EPS beat(4)-14.73%
Min EPS beat(4)-47.45%
Max EPS beat(4)5%
EPS beat(8)5
Avg EPS beat(8)-4.74%
EPS beat(12)8
Avg EPS beat(12)3.08%
EPS beat(16)11
Avg EPS beat(16)3.15%
Revenue beat(2)1
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-8.66%
Max Revenue beat(2)5.4%
Revenue beat(4)1
Avg Revenue beat(4)-14.96%
Min Revenue beat(4)-40.82%
Max Revenue beat(4)5.4%
Revenue beat(8)3
Avg Revenue beat(8)-11.95%
Revenue beat(12)3
Avg Revenue beat(12)-37.01%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)9.11%
PT rev (3m)17.56%
EPS NQ rev (1m)2.24%
EPS NQ rev (3m)3.08%
EPS NY rev (1m)0%
EPS NY rev (3m)7.95%
Revenue NQ rev (1m)-2.31%
Revenue NQ rev (3m)-2.31%
Revenue NY rev (1m)-1.02%
Revenue NY rev (3m)-3.05%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.66
P/FCF N/A
P/OCF N/A
P/B 2.51
P/tB 4.19
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.51
Fwd EYN/A
FCF(TTM)-0.82
FCFYN/A
OCF(TTM)-0.73
OCFYN/A
SpS0.64
BVpS1.7
TBVpS1.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.82%
ROE -55.97%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 28.66%
FCFM N/A
ROA(3y)-46.87%
ROA(5y)-48.85%
ROE(3y)-61.44%
ROE(5y)-63.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.29
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 94.15%
Cap/Sales 12.84%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.2
Quick Ratio 2.83
Altman-Z -0.1
F-Score4
WACC8.7%
ROIC/WACCN/A
Cap/Depr(3y)77.2%
Cap/Depr(5y)331.82%
Cap/Sales(3y)631.42%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)13.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.77%
EPS Next Y54.18%
EPS Next 2Y34.08%
EPS Next 3Y27.13%
EPS Next 5Y20.21%
Revenue 1Y (TTM)60.6%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%17.74%
Revenue Next Year49.67%
Revenue Next 2Y50.68%
Revenue Next 3Y45.74%
Revenue Next 5Y27.64%
EBIT growth 1Y-2.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.83%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y7.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.33%
OCF growth 3YN/A
OCF growth 5YN/A

IOVANCE BIOTHERAPEUTICS INC / IOVA FAQ

What is the fundamental rating for IOVA stock?

ChartMill assigns a fundamental rating of 2 / 10 to IOVA.


What is the valuation status for IOVA stock?

ChartMill assigns a valuation rating of 1 / 10 to IOVANCE BIOTHERAPEUTICS INC (IOVA). This can be considered as Overvalued.


How profitable is IOVANCE BIOTHERAPEUTICS INC (IOVA) stock?

IOVANCE BIOTHERAPEUTICS INC (IOVA) has a profitability rating of 1 / 10.


Can you provide the financial health for IOVA stock?

The financial health rating of IOVANCE BIOTHERAPEUTICS INC (IOVA) is 3 / 10.